ABIVAX (EPA:ABVX) | WebDisclosure

PRESS RELEASE

published on 07/23/2025 at 22:15, 6 months 12 days ago

Abivax Announces Launch of Public Offering
Abivax announces launch of $400 million public offering to fund therapeutics for chronic inflammatory diseases. Underwritten by Leerink Partners, Piper Sandler, Guggenheim Securities, with LifeSci Capital, BTIG, Van Lanschot Kempen as managers

Biotechnology Financing Abivax Underwriters Public Offering
BRIEF

published on 07/22/2025 at 22:10, 6 months 13 days ago

Abivax Announces Positive Phase 3 Results for Obefazimod in Ulcerative Colitis

Abivax Obefazimod Ulcerative Colitis Phase 3 Trials MiR-124 Enhancer
BRIEF

published on 07/22/2025 at 22:10, 6 months 13 days ago

Abivax annonce des résultats positifs de phase 3 pour l'obéfazimod dans la rectocolite hémorragique

Abivax Obefazimod Rectocolite Hémorragique Essais De Phase 3 Amplificateur MiR-124
PRESS RELEASE

published on 07/22/2025 at 22:06, 6 months 13 days ago

Abivax annonce des résultats positifs de phase 3 pour les deux essais d'induction ABTECT de 8 semaines, évaluant obefazimod dans le traitement de la rectocolite hémorragique
Abivax annonce des résultats positifs de phase 3 pour les essais ABTECT évaluant obefazimod dans la rectocolite hémorragique. Conférence prévue

Abivax Obefazimod Rectocolite Hémorragique Phase 3 Résultats Positifs
PRESS RELEASE

published on 07/22/2025 at 22:06, 6 months 13 days ago

Abivax annonce des résultats positifs de phase 3 pour les deux essais d'induction ABTECT de 8 semaines, évaluant obefazimod dans le traitement de la rectocolite hémorragique
Abivax annonce des résultats positifs de phase 3 pour les essais d'induction ABTECT de 8 semaines, évaluant obefazimod dans le traitement de la rectocolite hémorragique. Résultats de top-line prometteurs

Abivax Obefazimod Rectocolite Hémorragique Phase 3 Top-line
PRESS RELEASE

published on 07/22/2025 at 22:05, 6 months 13 days ago

Abivax Announces Positive Phase 3 Results from Both ABTECT 8-Week Induction Trials Investigating Obefazimod, its First-in-Class Oral miR-124 Enhancer, in Moderate to Severely Active Ulcerative Colitis
Abivax announces positive Phase 3 results for obefazimod in ulcerative colitis trials, meeting key endpoints and demonstrating favorable tolerability. Conference call scheduled for more insights

Abivax Obefazimod Ulcerative Colitis Clinical Trials Phase 3 Results
BRIEF

published on 07/17/2025 at 18:05, 6 months 18 days ago

ABIVAX : Détails sur le capital social et les droits de vote

Nombre D'actions Droits De Vote Capital Social Abivax Investisseurs
BRIEF

published on 07/17/2025 at 18:05, 6 months 18 days ago

ABIVAX: Details on share capital and voting rights

Share Capital Voting Rights Investors Abivax Number Of Shares
PRESS RELEASE

published on 07/17/2025 at 18:00, 6 months 18 days ago

ABIVAX: Nombre d’actions composant le capital social et nombre total de droits de vote
ABIVAX communique le nombre d'actions composant son capital social et le nombre total de droits de vote conformément aux dispositions réglementaires

Droits De Vote Capital Social Abivax Information Réglementaire Société Biotechnologie
BRIEF

published on 06/19/2025 at 18:05, 7 months 15 days ago

ABIVAX Déclare la Composition de son Capital Social et Droits de Vote

Euronext Paris Droits De Vote Capital Social Abivax Réglementation AMF

Published on 02/05/2026 at 16:40, 30 minutes ago

Relevant Gold Appoints Larry Taddei to Board of Directors and Mal Karwowska as Strategic Advisor
Published on 02/05/2026 at 15:45, 1 hour 25 minutes ago

American Critical Minerals Recaps a Highly Successful 6 Months and Files Amended and Restated Technical Report
Published on 02/05/2026 at 15:10, 2 hours ago

Electric Metals (USA) Limited Announces Change of Auditor
Published on 02/05/2026 at 14:50, 2 hours 20 minutes ago

High Tide Resources Announces Non-Brokered Private Placements
Published on 02/05/2026 at 14:30, 2 hours 40 minutes ago

Electrovaya Announces Date for Q1-2026 Financial Results & Conference Call

View all ACCESSWIRE

Published on 02/05/2026 at 17:05, 5 minutes ago

European Research and Innovation: the Politecnico di Milano Launches an Office in Brussels
Published on 02/05/2026 at 16:30, 40 minutes ago

Dividend Declaration
Published on 02/05/2026 at 16:20, 50 minutes ago

Original-Research: Deutsche Rohstoff AG (von First Berlin Equity Research GmbH): Buy
Published on 02/05/2026 at 16:20, 50 minutes ago

Birla Carbon Launches New Continua™ SCM Production Line in Italy
Published on 02/05/2026 at 15:56, 1 hour 14 minutes ago

Original-Research: Verve Group SE (von First Berlin Equity Research GmbH): Kaufen

View all EQS

Published on 02/05/2026 at 16:35, 35 minutes ago

Voting rights
Published on 02/05/2026 at 16:35, 35 minutes ago

Droits de vote
Published on 02/05/2026 at 16:04, 1 hour 6 minutes ago

MONTHLY INFORMATION CONCERNING THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES
Published on 02/05/2026 at 16:02, 1 hour 8 minutes ago

INFORMATION MENSUELLE RELATIVE AU NOMBRE TOTAL D'ACTIONS ET DE DROITS DE VOTE COMPOSANT LE CAPITAL
Published on 02/05/2026 at 11:30, 5 hours 40 minutes ago

Déclaration nombre d'actions et droits de vote - 05.02.2026

View all LES ECHOS COMFI WIRE

News